Post-trial access to treatment
Corporate best practices
The paper Post-Trial Acces To Treatment (PTA) offers an insight into current corporate policies and corporate best practices relating to the provision of PTA in low and middle income countries based on company sources. In these countries there is a greater appeal for pharmaceutical companies to take responsibility for providing PTA. However, the practice of providing PTA is the exception rather than the rule.
Do you need more information?
Download: Post-trial-access-to-treatment (pdf, 264.48 KB)